drugset / Trial / NCT02065375

RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery

NCT02065375

Phase 2 Completed 109 enrolled Biogen AbbVie · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This study assesses the efficacy and safety of two concentrations of RTA 408 Ophthalmic Suspension in the treatment of patients who have inflammation and pain following ocular surgery.

Timeline

Start
2014-02-28
Primary completion
2014-09-30
Completion
2014-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Omaveloxolone Small molecule 0.5 % Other
Subject Omaveloxolone Small molecule 1 % Other

Indications